Search research articles
Contact Us
Filters
Showing results (11-20 of 30) with videos related to
Page
of 3
Sort By:
Haematologica
|
March 3, 2009
Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration
Evangelos Terpos, Eirini Katodritou, Evangelos Tsiftsakis, et al.
American Journal of Hematology
|
September 16, 2011
Tumor-primed natural killer cells from patients with multiple myeloma lyse autologous, NK-resistant, bone marrow-derived malignant plasma cells
Eirini Katodritou, Evangelos Terpos, Janet North, et al.
British Journal of Haematology
|
November 17, 2006
Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma
Evangelos Terpos, Deborah J Heath, Amin Rahemtulla, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 7, 2009
Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw
Konstantinos Vahtsevanos, Athanassios Kyrgidis, Evgenia Verrou, et al.
American Journal of Hematology
|
February 1, 2024
Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide-exposed patients after one prior line of therapy: Final results of the phase 2 study DARIA
Evangelos Terpos, Ioannis Ntanasis-Stathopoulos, Maria Gavriatopoulou, et al.
Frontiers in Oncology
|
July 9, 2025
Case Report: Sequential lymphomas: may HLA system play a role in this uncommon phenomenon?
Evgenia Verrou, Ioanna Diamanti, Asimina Fylaktou, et al.
American Journal of Hematology
|
October 15, 2013
Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study group
Eirini Katodritou, Evangelos Terpos, Charikleia Kelaidi, et al.
Cancers
|
June 10, 2022
Daratumumab Improves Bone Turnover in Relapsed/Refractory Multiple Myeloma; Phase 2 Study "REBUILD"
Evangelos Terpos, Ioannis Ntanasis-Stathopoulos, Efstathios Kastritis, et al.
International Journal of Cancer
|
December 17, 2024
Incidence, characteristics and outcome of therapy-related myeloid neoplasms in women with epithelial ovarian cancer after exposure to poly-ADPribose polymerase inhibitors: A cancer center experience
Evgenia Verrou, Prodromos Koutoukoglou, Evangelia Kontana, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
February 7, 2025
Evaluation of Clinical Characteristics and Prognostic Factors of Early Progressive Disease (EPD) in Newly Diagnosed Multiple Myeloma Patients: Real-World Data of the Greek Myeloma Study Group
Eirini Katodritou, Efstathios Kastritis, Dimitra Dalampira, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 30) with videos related to
Sort By:
Page
of 3
Haematologica
|
March 3, 2009
Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration
Evangelos Terpos, Eirini Katodritou, Evangelos Tsiftsakis, et al.
American Journal of Hematology
|
September 16, 2011
Tumor-primed natural killer cells from patients with multiple myeloma lyse autologous, NK-resistant, bone marrow-derived malignant plasma cells
Eirini Katodritou, Evangelos Terpos, Janet North, et al.
British Journal of Haematology
|
November 17, 2006
Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma
Evangelos Terpos, Deborah J Heath, Amin Rahemtulla, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 7, 2009
Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw
Konstantinos Vahtsevanos, Athanassios Kyrgidis, Evgenia Verrou, et al.
American Journal of Hematology
|
February 1, 2024
Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide-exposed patients after one prior line of therapy: Final results of the phase 2 study DARIA
Evangelos Terpos, Ioannis Ntanasis-Stathopoulos, Maria Gavriatopoulou, et al.
Frontiers in Oncology
|
July 9, 2025
Case Report: Sequential lymphomas: may HLA system play a role in this uncommon phenomenon?
Evgenia Verrou, Ioanna Diamanti, Asimina Fylaktou, et al.
American Journal of Hematology
|
October 15, 2013
Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study group
Eirini Katodritou, Evangelos Terpos, Charikleia Kelaidi, et al.
Cancers
|
June 10, 2022
Daratumumab Improves Bone Turnover in Relapsed/Refractory Multiple Myeloma; Phase 2 Study "REBUILD"
Evangelos Terpos, Ioannis Ntanasis-Stathopoulos, Efstathios Kastritis, et al.
International Journal of Cancer
|
December 17, 2024
Incidence, characteristics and outcome of therapy-related myeloid neoplasms in women with epithelial ovarian cancer after exposure to poly-ADPribose polymerase inhibitors: A cancer center experience
Evgenia Verrou, Prodromos Koutoukoglou, Evangelia Kontana, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
February 7, 2025
Evaluation of Clinical Characteristics and Prognostic Factors of Early Progressive Disease (EPD) in Newly Diagnosed Multiple Myeloma Patients: Real-World Data of the Greek Myeloma Study Group
Eirini Katodritou, Efstathios Kastritis, Dimitra Dalampira, et al.
Page
of 3